Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00828425
Other study ID # NIS-CCH-DUM-2008/1
Secondary ID
Status Completed
Phase N/A
First received January 23, 2009
Last updated August 17, 2010
Start date December 2008
Est. completion date August 2009

Study information

Verified date August 2010
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority Switzerland: Ethikkommission
Study type Observational

Clinical Trial Summary

Aim of this NIS is to retrospectively document the management of diabetic patients with retinopathy in a naturalistic setting in Switzerland. Following elements are going to be analyzed:

- which medication are used to keep blood pressure under control?

- which medication are used for metabolic control?

- the average control level of metabolism and blood pressure is compliant with the international guidelines?

- laser photocoagulation plays a role in the control of metabolism and blood pressure?

- there are differences in the control of metabolism and blood pressure between patients with DM I or DM II?

- there is an influence of renal failure on the choose of medication?


Recruitment information / eligibility

Status Completed
Enrollment 2500
Est. completion date August 2009
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- Diabetic patients

- Diabetic retinopathy

Study Design

Time Perspective: Retrospective


Related Conditions & MeSH terms


Locations

Country Name City State
Switzerland Research Site Aigle VD
Switzerland Research Site Alle JU
Switzerland Research Site Ardon VS
Switzerland Research Site Ascona TI
Switzerland Research Site Basel BS
Switzerland Research Site Bassersdorf ZH
Switzerland Research Site Bassins VD
Switzerland Research Site Bern BE
Switzerland Research Site Bex VD
Switzerland Research Site Chateau-d'Oex VD
Switzerland Research Site Chur GR
Switzerland Research Site Clarens VD
Switzerland Research Site Collonge-Bellerive GE
Switzerland Research Site Dattwil AG
Switzerland Research Site Diegten BL
Switzerland Research Site Egg b. Zurich ZH
Switzerland Research Site Estavayer-le-Lac FR
Switzerland Research Site Evionnaz VS
Switzerland Research Site Eysins VD
Switzerland Research Site Fribourg FR
Switzerland Research Site Geneve GE
Switzerland Research Site Hausen b. Brugg AG
Switzerland Research Site Ilanz GR
Switzerland Research Site Kerns OW
Switzerland Research Site Kreuzlingen TG
Switzerland Research Site Kussnacht am Rigi SZ
Switzerland Research Site Laufen BL
Switzerland Research Site Lausanne VD
Switzerland Research Site Le Grand-Saconnex GE
Switzerland Research Site Le Locle NE
Switzerland Research Site Lenzburg AG
Switzerland Research Site Les Acacias GE
Switzerland Research Site Locarno TI
Switzerland Research Site Lugano TI
Switzerland Research Site Lupfig AG
Switzerland Research Site Luzern LU
Switzerland Research Site Moutier BE
Switzerland Research Site Muri AG AG
Switzerland Research Site Nyon VD
Switzerland Research Site Oberuzwil SG
Switzerland Research Site Prilly VD
Switzerland Research Site Renens VD VD
Switzerland Research Site Rheinfelden AG
Switzerland Research Site Rorschach SG
Switzerland Research Site Rothenburg LU
Switzerland Research Site Salavaux VD
Switzerland Research Site Samedan GR
Switzerland Research Site Saviese VS
Switzerland Research Site Schaffhausen SH
Switzerland Research Site Schinznach Dorf AG
Switzerland Research Site Sierre VS
Switzerland Research Site Sion VS
Switzerland Research Site Spreitenbach AG
Switzerland Research Site St-Legier VD
Switzerland Research Site St. Gallen SG
Switzerland Research Site Tuggen SZ
Switzerland Research Site Unterseen BE
Switzerland Research Site Versoix GE
Switzerland Research Site Vevey VD
Switzerland Research Site Viganello TI
Switzerland Research Site Wangs SG
Switzerland Research Site Winterthur ZH

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Blood lipids, glycemia, HbA1C, blood creatinine, proteinuria, body weight every 3 months No
Primary evolution of diabetic retinopathy every 3 months No
Secondary concomitant medication every 3 months No
See also
  Status Clinical Trial Phase
Completed NCT03743779 - Mastering Diabetes Pilot Study
Completed NCT03786978 - Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus N/A
Completed NCT01804803 - DIgital Assisted MONitoring for DiabeteS - I N/A
Completed NCT05039970 - A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04068272 - Safety of Bosentan in Type II Diabetic Patients Phase 1
Completed NCT03243383 - Readmission Prevention Pilot Trial in Diabetes Patients N/A
Completed NCT03730480 - User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS) N/A
Recruiting NCT02690467 - Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm. N/A
Completed NCT02229383 - Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus Phase 3
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Completed NCT06181721 - Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes N/A
Recruiting NCT04489043 - Exercise, Prediabetes and Diabetes After Renal Transplantation. N/A
Withdrawn NCT03319784 - Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients Phase 4
Completed NCT03542084 - Endocrinology Auto-Triggered e-Consults N/A
Completed NCT02229396 - Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo Phase 3
Recruiting NCT05544266 - Rare and Atypical Diabetes Network
Completed NCT01892319 - An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
Completed NCT05031000 - Blood Glucose Monitoring Systems: Discounter Versus Brand N/A
Recruiting NCT04039763 - RT-CGM in Young Adults at Risk of DKA N/A